Type 2 Diabetes | Current Treatment | EU5 | 2017
The type 2 diabetes market is expanding rapidly, fueled by increasing prevalence and a wave of recent product launches. Sanofi’s Suliqua (lixisenatide/insulin glargine), Novo Nordisk’s Fiasp, and AstraZeneca’s Glyxambi (linagliptin/empagliflozin) are examples of recent European product approvals. DRG believes the positive results from the EMPA-REGCVOT for Boehringer Ingelheim’s/Eli Lilly’s Jardiance will benefit uptake of the entire SGLT-2 inhibitor class. Current Treatment explores how the prescribing behaviors of European endocrinologists have changed in response to the rise of the SGLT-2 inhibitors and how other novel drugs compare.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
